HomeCompareMTOR vs ABBV

MTOR vs ABBV: Dividend Comparison 2026

MTOR yields 13.79% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $55.2K in total portfolio value· pulled ahead in Year 6
10 years
MTOR
MTOR
● Live price
13.79%
Share price
$36.50
Annual div
$5.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.5K
Annual income
$3,245.32
Full MTOR calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — MTOR vs ABBV

📍 ABBV pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTORABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTOR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTOR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTOR
Annual income on $10K today (after 15% tax)
$1,172.53/yr
After 10yr DRIP, annual income (after tax)
$2,758.52/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $19,108.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTOR + ABBV for your $10,000?

MTOR: 50%ABBV: 50%
100% ABBV50/50100% MTOR
Portfolio after 10yr
$77.1K
Annual income
$14,485.52/yr
Blended yield
18.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MTOR
Analyst Ratings
8
Buy
6
Hold
Consensus: Buy
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTOR buys
0
ABBV buys
0
No recent congressional trades found for MTOR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTORABBV
Forward yield13.79%3.12%
Annual dividend / share$5.04$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$49.5K$104.7K
Annual income after 10y$3,245.32$25,725.73
Total dividends collected$22.8K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: MTOR vs ABBV ($10,000, DRIP)

YearMTOR PortfolioMTOR Income/yrABBV PortfolioABBV Income/yrGap
1$12,079$1,379.45$11,559$438.51+$520.00MTOR
2$14,482$1,557.29$13,494$640.86+$988.00MTOR
3$17,241$1,744.93$15,951$945.97+$1.3KMTOR
4$20,389$1,941.41$19,152$1,413.89+$1.2KMTOR
5$23,962$2,145.72$23,443$2,146.38+$519.00MTOR
6← crossover$27,996$2,356.76$29,391$3,321.96$1.4KABBV
7$32,529$2,573.39$37,948$5,265.87$5.4KABBV
8$37,601$2,794.46$50,795$8,596.74$13.2KABBV
9$43,252$3,018.81$71,034$14,549.41$27.8KABBV
10$49,525$3,245.32$104,715$25,725.73$55.2KABBV

MTOR vs ABBV: Complete Analysis 2026

MTORStock

Meritor, Inc. designs, develops, manufactures, markets, distributes, sells, services, and supports integrated systems, modules, and components in North America, South America, Europe, and the Asia Pacific. It operates through two segments, Commercial Truck, and Aftermarket and Industrial. The company offers axles, including front steer and rear drive axles for medium- and heavy-duty commercial vehicles; heavy-duty trailer axles; suspension modules and brake products comprising drum and disc brakes; universal joints and driveline components; trailer air suspension systems and products; transfer cases and drivelines; and advanced suspension modules for use in light-, medium- and heavy-duty military tactical wheeled vehicles. It also provides air brakes, such as cam drum, wedge drum, and air disc brakes, as well as wheel-end components, including hubs, drums, and rotors to medium- and heavy-duty commercial vehicle manufacturers; and electric drive systems comprising electric motors and inverters, power electronics, battery pack, electrified accessories, and related software and controls for terminal tractors and medium and heavy-duty trucks and buses. In addition, the company sells other complementary products, including third-party and private label items, which include brake shoes and friction materials; automatic slack adjusters; yokes and shafts; wheel-end hubs and drums; ABS and stability control systems; shock absorbers and air springs; and air brakes. Meritor, Inc. sells its products under the Meritor, Euclid, Trucktechnic, US Gear, AxleTech, and Mach brands primarily to original equipment manufacturers, their parts marketing operations, and their dealers, as well as other independent distributors and service garages in the aftermarket industry. The company was formerly known as ArvinMeritor, Inc. and changed its name to Meritor, Inc. in March 2011. Meritor, Inc. was founded in 1909 and is headquartered in Troy, Michigan.

Full MTOR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MTOR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTOR vs SCHDMTOR vs JEPIMTOR vs OMTOR vs KOMTOR vs MAINMTOR vs JNJMTOR vs MRKMTOR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.